Wennan Chang, Changlin Wan, Yifan Sun, Yan Han, Siyuan Qi, Xiongbin Lu, Sha Cao, Chi Zhang
{"title":"Abstract 2439: A semi-supervised deconvolution method for quantifying the composition and activity of tumor-infiltrating cell types","authors":"Wennan Chang, Changlin Wan, Yifan Sun, Yan Han, Siyuan Qi, Xiongbin Lu, Sha Cao, Chi Zhang","doi":"10.1158/1538-7445.AM2019-2439","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-2439","url":null,"abstract":"Tumor microenvironment (TME) plays a key role in tumorigenesis, disease progression and the acquirement of drug resistance. An accurate assessment of TME cellular compositions may not only shed light on how TME interacts with cancer cells, but also bring new insights for translational researchers in studying the non-responding mechanism of immunotherapy. Traditional deconvolution methods infer the relative proportions of predefined cell types based on a tissue omics data through either regression- or enrichment- based approaches. However, there are several challenges that remain unsolved in the current formulations, including (1) identifying the Immune/Stromal (I/S) cell types that truly exists in a TME, (2) identifying the marker genes for each cell type that are specifically expressed by one or a few I/S cell types in a TME, (3) co-linearity among to-be-assessed I/S proportions due to their co-infiltration. We have developed a novel semi-supervised deconvolution method namely ICTD (Inference of Cell types and Deconvolution), addressing the three challenges via (i) developing a Bi-Cross Validation (BCV) based matrix rank test to assess the significance level of the existence of cell types and signature genes, (ii) utilizing a constrained Non-negative Matrix Factorization (NMF) to eliminate the effect of co-linearity. We validated ICTD on bulk tumor datasets simulated using single-cell RNA-seq data. Our analysis suggested that ICTD has a largely improved prediction accuracy of TME compositions comparing to existing methods, and particularly, it is capable of identifying novel or sub-cell types. We applied our method to TCGA and other gene expression data of breast and prostate cancer. Subsets of CD8+ T cells with varied cytotoxicity levels and subtypes of fibroblast cells were identified. Moreover, integrated with an analysis of an independent single-cell and cell line gene expression dataset, we identified genes specifically expressed by cancer cells that are associated with decreased T cell cytotoxicity level. Citation Format: Wennan Chang, Changlin Wan, Yifan Sun, Yan Han, Siyuan Qi, Xiongbin Lu, Sha Cao, Chi Zhang. A semi-supervised deconvolution method for quantifying the composition and activity of tumor-infiltrating cell types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2439.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129528226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Pyo, B. Ahn, Chun-Feng Xin, Dongmin Jung, C. Kim, M. Hong, B. Cho, H. Kim
{"title":"Abstract 683: A machine learning based clinical decision support system (CDSS) for anti-PD-1 therapy using non-invasive blood marker and clinical information for lung cancer patients","authors":"K. Pyo, B. Ahn, Chun-Feng Xin, Dongmin Jung, C. Kim, M. Hong, B. Cho, H. Kim","doi":"10.1158/1538-7445.AM2019-683","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-683","url":null,"abstract":"Cancer immunotherapy with anti-PD-1 therapy (αPD-1) has greatly improved the survival outcome of patients with non-small cell lung cancer (NSCLC). However, the response rates of αPD-1 are around 20-30% based on clinical trials. The presence of PD-L1, tumor infiltrating lymphocyte or tumor mutation burden may be used as indicators of response, but are still limited to predict αPD-1 response. In this study, we established the machine learning based clinical decision support system (CDSS) to predict the αPD-1 response by comprehensively combining clinical information and blood-based data which are easily assessable in routine practice.We enrolled 126 patients with NSCLC treated with the αPD-1 at Yonsei cancer center. Clinical data including patient characteristics, mutation, treatment outcomes, and adverse events were collected and analyzed. Forty patients additionally had blood-based immune data by flow cytometry. There were two data sets; clinical data set (n=126) with 15 variables, and immune data set (n=40) with 37 variables. We found that 27 variables out of 52 variables are selected by recursive feature elimination. The responders are defined as PR or SD ≥6 months and the non-responders are defined as the others. Supervised learning algorithms such as the LASSO, Ridge, Elastic Net, SVM, ANN, and RF were applied to each data set for predicting the αPD-1 response. The performances of each model were evaluated according to the ROC curve or cross-validation errors. Variable importance was measured by using the random forest and gradient boosting.Patient characteristics included male (69.8%), age ≥ 60 years (66.2%), ECOG 0/1 (77.7%), adenocarcinoma (69.8%), EGFR mutations (15.1%), and PD-L1 positive (61.2%). We classified the patients into responders (38%) and non-responders (62%) in total 126 patients. A result from the clinical data set of 126 patients demonstrated that the Ridge regression model (AUC: 0.78) can more accurately predict the αPD-1 response than others. Of 15 clinical variables, some are considered to be important in the following order; tumor burden,age, PD-L1, ECOG PS, and irAE based on the random forest. When we performed the machine learning process with clinical and immune data, The Ridge regression model (AUC:0.82) showed the good performance to predict αPD-1 response, compared to the single clinical model. The machine learning based CDSS for aPD-1 to NSCLC patients has benefit for predicting aPD-1 responses. Our prediction model could be easily accessible and fast processed in routine practice. The supervised machine learning based non-invasive predictive score (NIPS) demonstrates the rate of aPD-1 response on NSCLC patients. We will validate NIPS in independent patient cohort and currently are establishing the NIPS as web-based software. Citation Format: Kyoung-Ho Pyo, Beung-Chul Ahn, Chun-Feng Xin, Dongmin Jung, Chang Gon Kim, Min Hee Hong, Byoung Chul Cho, Hye Ryun Kim. A machine learning based clinical decision support sy","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129658159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chia-Ling Huang, Andrew Yang, Ted E. Natoli, Lev Litichevskiy, F. Vaillancourt, A. Rolfe, Yonghong Xiao, A. Subramanian, Lihua Yu
{"title":"Abstract 2467: Heme-CMap: Generation and characterization of ~20K L1000 profiles across 11 hematologic malignant lines","authors":"Chia-Ling Huang, Andrew Yang, Ted E. Natoli, Lev Litichevskiy, F. Vaillancourt, A. Rolfe, Yonghong Xiao, A. Subramanian, Lihua Yu","doi":"10.1158/1538-7445.SABCS18-2467","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2467","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127371958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Noorbakhsh, Saman Farahmand, Mohammad Soltanieh Ha, Sandeep Namburi, Kourosh Zarringhalam, Jeffrey H. Chuang
{"title":"Abstract 1632: Deep learning functional associations using histopathology images","authors":"J. Noorbakhsh, Saman Farahmand, Mohammad Soltanieh Ha, Sandeep Namburi, Kourosh Zarringhalam, Jeffrey H. Chuang","doi":"10.1158/1538-7445.SABCS18-1632","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1632","url":null,"abstract":"Histopathological images have critical value for understanding cancer subtype, local structure, and malignancy. Manual interpretation of such images can be time-consuming and error-prone, while also failing to make use of the power of image aggregation for coordinated data mining. Large-scale patient cohorts such as TCGA provide high-resolution HE 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1632.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130057167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 2479: A survey of molecular factors of DNA methylation and demethylation in a broad range of cancer cell lines","authors":"Suleyman Vural, J. Krushkal","doi":"10.1158/1538-7445.SABCS18-2479","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2479","url":null,"abstract":"DNA methylation has a powerful influence on cellular processes. It plays important roles in cancer initiation and progression. Cancer cells exhibit frequent epigenomic alterations that affect expression of genes involved in apoptosis, cell proliferation, and DNA repair. We used expression information of known methylating and demethylating genes in cancer cell lines to analyze their association with methylation levels of individual probes and median epigenome-wide methylation levels. We utilized RNA-seq gene expression measures and Illumina Infinium HumanMethylation450 BeadChip DNA methylation data of 645 cancer cell lines from 23 cancer types from the Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in Cancer resources. We analyzed 73 genes, products of which are involved in methylation and demethylation processes, and examined correlations between expression levels of these genes and methylation status of individual probes and epigenome-wide. In a combined analysis across all cancer types, we observed statistically significant correlations between expression of global DNA methyltransferase genes, DNMT1 , DNMT3A , and DNMT3B , and probe methylation levels in 566, 909, and 230 genes, respectively. In particular, DNMT3A expression was associated with methylation status of growth factor and receptor genes FGF1 , FGFR4 , and EGFR . Expression of hydroxymethylating genes TET1 , TET2 , and TET3 was correlated with methylation status of probes in 363, 1, and 1055 genes, respectively, including associations of TET3 expression with methylation of probes in the FGF1 , KIT , FHIT , IGF1R , IGF2BP2 , and PARP3 genes, which may affect growth, proliferation, and DNA repair of tumor cells. APOBEC1 , CBX2 , UHRF1 and ZBTB38 , products of which are involved in various molecular steps of DNA methylation or demethylation, had the largest numbers of associations in different cancer types. For example, in chronic lymphocytic leukemia cell lines we observed a strong negative correlation between ZBTB38 expression, the product of which binds methylated DNA, and methylation levels of probes in 204 genes. We also found a strong correlation between UHRF1 gene expression and methylation levels of probes in 150 genes in chronic lymphocytic leukemia cell lines, in agreement with reported roles of the product of this gene in binding DNA methyltransferases and affecting DNMT1 methylation activity. These results provide a better understanding of molecular mechanisms of epigenetic dysregulation in cancer cells and may provide strategies for future analysis of molecular targets of drug response that may be affected via epigenetic processes. Citation Format: Suleyman Vural, Julia Krushkal. A survey of molecular factors of DNA methylation and demethylation in a broad range of cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Su","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126346428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 1678: Accurate detection of expressed variation in RNA-seq","authors":"Lisle E. Mose, David L. Marron, J. Parker","doi":"10.1158/1538-7445.SABCS18-1678","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1678","url":null,"abstract":"Somatic variant detection has long been an area of great interest and critical importance in cancer research and treatment. DNA-Seq based somatic variant calling pipelines have been maturing over the last several years and although there is still room for improvement, several methods have been developed capable of accurately detecting somatic variants from matched tumor/normal DNA. RNA-Seq has become a widely used tool for measuring gene and isoform abundance, identifying alternative splicing, and detection of gene fusions. Detection of expressed variation is receiving growing interest, however computational methods to detect this variation have received far less attention than that of DNA-Seq. We have developed an optimized RNA-Seq pipeline based upon the ABRA2 realigner capable of accurately detecting expressed somatic variation in RNA-Seq. We applied this pipeline to the TCGA Breast Cancer dataset. To assess the impact of identification of expressed variation as an indicator of variant significance, we compared the expression state of the top 20 cohort wide significantly mutated genes (SMG) as identified by The Cancer Genome Atlas Network (2012) with all other genes. At the median for SMGs, 23 somatic variants are expressed with over 90% of variants detected in DNA being expressed. For non-SMGs, the median number of expressed variants is 1 and the median fraction of expressed variants is 50%. Among non-SMGs, a total of six genes exceed the median total number of expressed variants and fraction of expressed variants for SMGs (AHNAK, CHD4, ERBB2, FASN, FOXA1 and MYH9). All of these variants have been previously implicated in breast cancer, however none of these variants were among the cohort wide SMGs identified in the original study and only FOXA1 was identified as being a subtype specific SMG (ER+,ER+/HER2-). Notably, variants in the massive TTN gene are found to be coding 73% of the time, but expressed in only 8% of cases. This is substantially less than the 90% found in SMGs and a likely indicator that TTN mutations are passenger variants. The median and third quartile RNA variant allele frequency (VAF) for SMGs is .41 and .69 versus .32 and .46 for DNA. By comparison, the median and third quartile VAF for non-SMGS was 0 and .27 in RNA and .20 and .30 for DNA. The increased VAF for RNA SMGs is a likely indicator of selection and can potentially further be used to identify variants of significance. We believe these results demonstrate the utility of variant expression as a potentail tool to aid in assessment of variant significance. Citation Format: Lisle E. Mose, David Marron, Joel S. Parker. Accurate detection of expressed variation in RNA-seq [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1678.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121509497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Subat, K. Inamura, H. Ninomiya, H. Nagano, S. Okumura, Y. Ishikawa
{"title":"Abstract 2440: The microRNA-mRNA interactions inALK-rearranged lung adenocarcinoma","authors":"S. Subat, K. Inamura, H. Ninomiya, H. Nagano, S. Okumura, Y. Ishikawa","doi":"10.1158/1538-7445.SABCS18-2440","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2440","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122321850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 5112: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types","authors":"S. Vasaikar, P. Straub, Jing Wang, Bing Zhang","doi":"10.1158/1538-7445.AM2019-5112","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5112","url":null,"abstract":"Background: The Cancer Genome Atlas (TCGA) project has performed molecular profiling of human tumors using genomic, epigenomic, transcriptomic, and proteomic platforms, and each tumor is comprehensively characterized by around 100,000 molecular attributes in addition to typical clinical attributes. To make these data directly available to the entire cancer research community, several data portals have been developed. However, none of the existing data portals allow systematic exploration and interpretation of the complex relationships between the vast amount of clinical and molecular attributes. Methods: We developed LinkedOmics (http://www.linkedomics.org), a web platform that focuses on the discovery and interpretation of associations between clinical and molecular attributes. LinkedOmics includes three data analysis modules. The LinkFinder module allows flexible exploration of associations between a molecular or clinical attribute of interest and all other attributes, providing the opportunity to analyze and visualize associations between billions of attribute pairs for each cancer cohort. The LinkCompare module enables easy comparison of the associations identified by LinkFinder, which is particularly useful in multi-omics and pan-cancer analyses. The LinkInterpreter module transforms identified associations into biological understanding through pathway and network analysis. All modules provide user-friendly data visualization. Results: The current version of LinkedOmics contains multi-omics data and clinical data for 32 cancer types and a total of 11,158 patients from the TCGA project. Currently we have ~50 PDX (patient derived xenograft) samples data. It is also the first multi-omics database that integrates mass spectrometry (MS)-based global proteomics data generated by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) on selected TCGA tumor samples, as well as CPTAC Colon, Endometrial, Kidney and Breast cancer. In total, LinkedOmics has more than a billion data points. We used several case studies to demonstrate the utility of LinkedOmics in revealing functional impact of somatic mutation or copy number alteration on mRNA or protein expression, in deriving multi-omics based protein signature for poor prognosis, in performing pan-cancer analysis to identify survival-associated gene expression signature, and in connecting novel pan-cancer poor prognosis markers to tumor invasiveness and aggressiveness. Conclusions: LinkedOmics provides a unique platform for biologists and clinicians to access, analyze and compare cancer multi-omics data within and across tumor types. With 5 case studies we demonstrated the power of LinkedOmics in cancer research. Although the current version of LinkedOmics includes only TCGA and CPTAC data, it can be easily extended to support other cohort-based or user provided multi-omics studies. Citation Format: Suhas Vasaikar, Peter Straub, Jing Wang, Bing Zhang. LinkedOmics: Analyzing multi-omics data within a","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126028568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 4260: Novel insights into immunotherapy by deep mining of big cancer genomic data","authors":"Han Liang","doi":"10.1158/1538-7445.SABCS18-4260","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4260","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"1087 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116037918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zbyslaw Sondka, H. Speedy, S. Bamford, C. Cole, Sari Ward, S. Forbes
{"title":"Abstract 2469: The COSMIC Cancer Gene Census - a comprehensive study of all mutated cancer-driving genes","authors":"Zbyslaw Sondka, H. Speedy, S. Bamford, C. Cole, Sari Ward, S. Forbes","doi":"10.1158/1538-7445.SABCS18-2469","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2469","url":null,"abstract":"The COSMIC Cancer Gene Census (https://cancer.sanger.ac.uk/census) is a catalogue of genes that drive all forms of human cancer. Since 2004, a consistent curation approach to the scientific literature has grown this resource into a comprehensive description of 723 genes, detailing how each gene contributes to disease causation The entire Cancer Gene Census has been fully re-evaluated, and each gene has been classified as Oncogene, Tumour Suppressor and/or Fusion gene - depending on their somatic mutation profile and functional role in carcinogenesis. Genes included in the CGC are characterised by the presence of somatic or germline mutations, which change the activity or expression of the protein product in a way that promotes one or multiple hallmarks of cancer. The minimum level of evidence required for CGC inclusion are at least 2 publications from independent research groups showing increased mutation frequency in at least one type of cancer; and 2 or more published experimental evidence of functional involvement of a gene in promoting the hallmarks of cancer. The functional description of how each mutated gene causes cancer is now underway, with approximately half the Census now described in both functional and mechanistic terms. These characteristics clearly show that many genes can participate in oncogenesis in multiple ways that are highly dependent on the type of genetic alteration and tissue in which the gene is expressed, as well as disease stage. Alongside this evidence-based characterisation of genes we know drive cancer, a “second tier” of genes is now encompassed in the Census, to describe genes implicated in oncology, but with less robust published evidence. These genes, often revealed by combining whole-tumour-genome sequencing studies are increasing rapidly in number and often underpin exciting new targets in oncology. Inclusion of these in the Census completes its ability to describe the contribution of inherited and acquired genetics to human oncology. With substantial research ongoing, the Census is updated with additional content every three months, included with every new release of the COSMIC database (https://cancer.sanger.ac.uk/). Citation Format: Zbyslaw Sondka, Helen E. Speedy, Sally Bamford, Charlotte G. Cole, Sari A. Ward, Simon A. Forbes. The COSMIC Cancer Gene Census - a comprehensive study of all mutated cancer-driving genes [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2469.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"254 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116058279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}